<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04069117</url>
  </required_header>
  <id_info>
    <org_study_id>R.19.07.557</org_study_id>
    <nct_id>NCT04069117</nct_id>
  </id_info>
  <brief_title>Follicular Synchronization in Polycystic Ovarian Syndrome Patients Undergoing Intracytoplasmatic Sperm Injection ( ICSI )</brief_title>
  <official_title>Follicular Synchronization in Polycystic Ovarian Syndrome Patients Undergoing Intracytoplasmatic Sperm Injection With Letrozole /Antagonist Protocol: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of GnRH antagonist protocol nowadays is the slandered protocol of controlled ovarian
      stimulation in patients with poly cystic ovarian syndrome (PCOS) because it decreases the
      incidence of OHSS(1, 2). However, this protocol may lead to asynchronous growth of follicles
      with an early dominant follicle specially in PCOS patients(3). In most of cases this
      phenomenon will affect the IVF outcomes(2, 4) Aromatase inhibitors (AIs) nowadays is
      recommended to be used for ovulation induction in patients with PCOS (5, 6).It has fewer side
      effects, and a shorter half-life than clomiphene citrate(CC), and no effect ON the
      endometrial receptivity. It is used in treating patients with chronic anovulation,
      unexplained infertility and poor ovarian reserve(7). It acts through decreasing estrogen
      levels and allows follicle stimulating hormone (FSH) release from the hypothalamus (8, 9). It
      could be used alone or with combination with human menopausal gonadotropin (HMG) specially in
      patients with CC resistant(10-13). It also improves the ovarian response to FSH when they are
      used in combination and it decreases the risk of OHSS (14).

      This study aims to evaluate the effect of uses of letrozole in combination with HMG during
      ovarian stimulation in patients having PCOS undergoing IVF/ICSI on the follicular growth
      pattern, synchronized growth of follicles, maturity of oocyte and the quality of embryos.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants in this study will be group of subfertile women undergoing IVF/ ICSI trial and
      having polycystic ovarian syndrome Inclusion criteria

        1. Ages ≥20 and &lt;40 years old

        2. Women having the diagnosis of polycystic ovarian syndrome according to Rotterdam
           criteria (15)

        3. Women who have at least one of the following indications for IVF or ICSI:

             1. Resistance to slandered ovulation induction and life style modification

             2. Tubal factors: unilateral or bilateral tubal obstruction, unilateral or bilateral
                salpingectomy or tubal ligation

             3. Male factors: oligoasthenozoospermia or obstructive azoospermia Exclusion criteria

      1. Women with unexplained infertility. 2. women with poor ovarian reserve according to
      Bologna criteria (16). 3. Couples with known chromosomal abnormalities. 4. Women who refuse
      to participate in this study.

      Methods

        -  patients will be randomly assigned into two groups (100 patients in each group):
           letrozole group (study group) and non letrozole group (control group). Treatment
           assignment will be blinded to patients, physicians, and nursing staff.

        -  All patients will receive combined oral pills before stimulation.

        -  letrozole 2.5mg twice daily (Femara; Novartis Pharma Services, Basel, Switzerland) will
           be given for 5 days starting from the second day of menstruation in combination with low
           dose step up stimulation with recombinant FSH in the study group.

        -  Allocated patients will be randomized into either of two groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blinded clinical trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>the number of asynchronized follicles in both groups</measure>
    <time_frame>30 min</time_frame>
    <description>• Asynchronization will considered when there is a difference of at least 2 mm between the dominant follicle and other follicles</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Polycystic Ovarian Syndrome</condition>
  <arm_group>
    <arm_group_label>• Study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>It contains 100 patients will undergo ovarian stimulation with letrozole 2.5mg twice daily (Femara; Novartis Pharma Services, Basel, Switzerland) for 5 days starting from the first day of menstruation in combination with low dose step up stimulation with recombinant FSH starting in the third day of menstruation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>• Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>It contains 100 patients will undergo ovarian stimulation with low dose step up stimulation with recombinant FSH starting in the third day of menstruation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)</intervention_name>
    <description>letrozole /antagonist protocol</description>
    <arm_group_label>• Study group</arm_group_label>
    <other_name>letroz 2.5mg (Sun Pharmaceuticals Industries Ltd.,India)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Ages ≥20 and &lt;40 years old 2. Women having the diagnosis of polycystic ovarian
             syndrome according to Rotterdam criteria (15) 3. Women who have at least one of the
             following indications for IVF or ICSI:

               1. Resistance to slandered ovulation induction and life style modification

               2. Tubal factors: unilateral or bilateral tubal obstruction, unilateral or bilateral
                  salpingectomy or tubal ligation

               3. Male factors: oligoasthenozoospermia or obstructive azoospermia

        Exclusion Criteria:

          -  1. Women with unexplained infertility. 2. women with poor ovarian reserve according to
             Bologna criteria (16). 3. Couples with known chromosomal abnormalities. 4. Women who
             refuse to participate in this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>subfertile women undergoing IVF/ ICSI trial and having polycystic ovarian syndrome</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed E Taman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine - Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed E Taman, MD</last_name>
    <phone>+2001063516395</phone>
    <email>dr_mohammed_elsayed@mans.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed E Taman, MD</last_name>
    <phone>+2001063516395</phone>
    <email>dr_mohammed-elsayed@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>050</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed E. Taman, MD</last_name>
      <phone>+201063516395</phone>
      <email>dr_mohammed_elsayed@mans.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016 Apr 29;4:CD001750. doi: 10.1002/14651858.CD001750.pub4. Review.</citation>
    <PMID>27126581</PMID>
  </reference>
  <reference>
    <citation>Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018 Sep 1;33(9):1602-1618. doi: 10.1093/humrep/dey256. Erratum in: Hum Reprod. 2019 Feb 1;34(2):388.</citation>
    <PMID>30052961</PMID>
  </reference>
  <reference>
    <citation>Wang R, Mol BW. The Rotterdam criteria for polycystic ovary syndrome: evidence-based criteria? Hum Reprod. 2017 Feb;32(2):261-264. doi: 10.1093/humrep/dew287. Epub 2016 Nov 9.</citation>
    <PMID>28119448</PMID>
  </reference>
  <reference>
    <citation>Ferraretti AP, Gianaroli L. The Bologna criteria for the definition of poor ovarian responders: is there a need for revision? Hum Reprod. 2014 Sep;29(9):1842-5. doi: 10.1093/humrep/deu139. Epub 2014 Jul 9.</citation>
    <PMID>25008235</PMID>
  </reference>
  <reference>
    <citation>Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018 May 24;5:CD010287. doi: 10.1002/14651858.CD010287.pub3. Review.</citation>
    <PMID>29797697</PMID>
  </reference>
  <reference>
    <citation>Zhao Y, Ruan X, Mueck AO. Letrozole combined with low dose highly purified HMG for ovulation induction in clomiphene citrate-resistant infertile Chinese women with polycystic ovary syndrome: a prospective study. Gynecol Endocrinol. 2017 Jun;33(6):462-466. doi: 10.1080/09513590.2017.1292241. Epub 2017 Feb 28.</citation>
    <PMID>28277124</PMID>
  </reference>
  <reference>
    <citation>Wang R, Kim BV, van Wely M, Johnson NP, Costello MF, Zhang H, Ng EH, Legro RS, Bhattacharya S, Norman RJ, Mol BW. Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ. 2017 Jan 31;356:j138. doi: 10.1136/bmj.j138. Review.</citation>
    <PMID>28143834</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University Hospital</investigator_affiliation>
    <investigator_full_name>Mohamed Taman</investigator_full_name>
    <investigator_title>lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

